{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 25 of 74', 'leaving an interval of approximately 12 hours between doses. When dabrafenib and', 'trametinib are taken in combination, the once-daily dose of trametinib should be taken', 'at the same time each day with either the morning dose or the evening dose of', 'dabrafenib.', 'Trametinib', 'Trametinib should be taken orally with a full glass of water. Trametinib tablets should', 'not be chewed or crushed. Trametinib should be taken without food, at least 1 hour', 'before or 2 hours after a meal.', 'It is recommended that the dose of trametinib is taken at a similar time every day.', 'When dabrafenib and trametinib are taken in combination, the once-daily dose of', 'trametinib should be taken at the same time each day with either the morning dose or', 'the evening dose of dabrafenib.', 'If a patient vomits after taking dabrafenib or trametinib, the patient should not retake', 'the dose. The next scheduled dose should be taken at the normal time.', 'For further details of administration of either IMP, refer to the current version of the', \"manufacturer's Summary of Product Characteristics (SmPC) for the brand used, which\", 'can be accessed via the Electronic Medicines Compendium (eMC) website:', 'http://www.medicines.org.uk/emo', '9.4 Drug storage, supply and accountability', '9.4.1', 'Supply', 'Both Dabrafenib and Trametinib are used within their licensed indication and general', \"'off the shelf' supplies will be used. There is no requirement to ring-fence 'off the shelf'\", 'supplies of dabrafenib and Trametinib for the INTERIM trial. Both IMPs will be handled', \"in line with manufacturer's recommendations. For further details, refer to the current\", \"version of the manufacturer's SmPC for the brand used.\", '9.4.2', 'Labelling (Type A)', 'Under the Article 14 of Directive 2001/20/EC allows for adaptable provisions relating to', 'labelling when the product does not require particular manufacturing or packaging', 'processes and has a marketing authorisation.', 'Dabrafenib and Trametinib will be used in accordance with the conditions set out in', 'Regulation 46 (2) of the Medicines for Human Use (Clinical Trials) Regulations 2004', '(and amended in 2006). As both IMPs will be used within their licensed indication and', 'under Type A categorisation, no special trial labelling requirements apply and both', 'dabrafenib and trametinib may be labelled in accordance with the requirements of', 'Schedule 5 to the Medicines for Human Use (Marketing Authorisation etc.) Regulations', '1994.', '9.4.3', 'Storage, Formulation and Preparation', 'Dabrafenib and Trametinib formulation, storage, and preparation are in line with the', \"manufacturers' recommendations. For further details, refer to the current version of the\", \"relevant manufacturer's SmPC (via http://www.medicines.org.uk/emc) for the brand\", 'used.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 26 of 74', '9.4.1Use of 3rd Party Supply and Delivery of IMP', 'IMP supply and/or delivery to a participant or their home by 3rd party home', 'community pharmacy or healthcare companies is permitted if this is in accordance with', 'routine NHS practice at the participating trial site. The trial does not require any', 'additional actions beyond existing standard care practices. CCTU should be informed', 'during the site set-up process, or if this is adopted during the life of the study.', '9.4.2', 'Accountability and Patient compliance ( patient diaries)', 'In this trial patient diaries and case report forms (CRF) will be used to capture', 'information of IMPs dispensed/used.', 'The sites will not require to keep detailed accountability records of batch numbers and', 'expiry dates of the IMPs dispensed.IMPs dispensed will be commercially available and', 'may also be dispensed by a third party other then the trial site.', 'Participating patients will be provided with a patient diary to keep detailed record of all', 'dabrafenib capsules and trametinib tablets taken by the patient during the trial.', 'Study-site personnel will review dosing information with the patient (or legally', 'authorised representative) on scheduled clinic visit days, providing instructions', 'regarding dose, dose frequency and the number of tablets/capsules to be taken for', 'each dose. Patients (or legally authorised representative) will be instructed to return all', 'unused tablets/capsules and containers (empty, partially used, and/or unopened) for', 'compliance check at the next scheduled clinic visits.', 'A compliance check and tablet/capsule count will be performed by study personnel', 'during clinic visits. Study site personnel will record compliance information on the case', 'report form (CRF).', '9.5 Known drug reactions & interaction with other therapies', 'For known drug reactions please refer to the current UK SmPCs for dabrafenib and', 'trametinib. The SmPC is updated from time to time. Up to date UK SmPCs are posted', 'on the Medicines Guide Website: http://www.medicines.org.uk', '9.6', 'Dosage modifications', '9.6.1', 'Dose level reduction guidelines', 'Dose level', 'Dabrafenib', 'Trametinib', 'Starting dose', '150mg bid', '2mg od', '1st dose reduction', '100mg bid', '1.5mg od', '2nd', 'dose reduction', '75 mg bid', '1mg od', '3rd dose reduction', '50mg bid', '1mg od', '9.6.2', 'Missed doses', 'If a dose of dabrafenib is missed at the normal time, it should not be taken if it is less', 'than 6 hours until the next dose.', 'If a dose of trametinib is missed at the normal time, only take the dose of trametinib if', 'it is more than 12 hours until the next scheduled dose.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}